Friday, June 24, 2022
HomeEditor PicksWhat Is Cgrp For Migraines

What Is Cgrp For Migraines

Cgrp Treatments For Prevention

How to Choose the Best CGRP Injectable for YOUR Migraines
  • Approved by US FDA on February 21, 2020, for prevention of Migraine in adults
  • The first anti-CGRP therapy to be administered in quarterly infusion
  • Manufactured by Lundbeck
  • The recommended dose is 100 mg every three months, although some may benefit from 300 mg
  • Studies show a single infusion reduced Migraine days in half of patients immediately following the first dose
  • About one-third of patients had a 75% or greater reduction in Migraine days through weeks 4 and 12
  • About 1 in 5 patients had a 100% response: no attacks 6 months after treatment

What Are My Chances Of Responding Positively To A Cgrp Antibody

See our other post on this topic for Aimovig . If there is an interest in this topic for more data about all the drugs more information could be made available.

A response rate is the proportion of people who will improve after taking a treatment. Example of 50% response: start with 12 days per month, down to 6Example of 75% response: start with 20 days per month, down to 5

What Symptoms Can Anti

Looking at some post-hoc analysis of the fremanezumab database, it seems that these antibodies actually provide crystal-clear days. On days when youre not having a migraine headache, it seems to improve quality of life, performance and wellness.

It may be that these antibodies clear up some of these non-headache symptom, like dizziness, brain fog, trouble concentrating and sensitivity to light. Some early indicators would seem to suggest that people feel better on days when they have headache, but also better, and clearer, on days when they dont have headache.

Read Also: How Common Are Visual Migraines

What Are The Side Effects Of Nurtec Odt And Ubrelvy

The side effect profile of the gepants is minimal and similar to placebo. The most common side effects of gepants are very low risk of nausea for Nurtec ODT and low risk of nausea and mild sedation with the higher dose of Ubrelvy. Side effects are discussed in more detail here.

In addition, there is no interaction with using them and triptans, NSAIDs, or other acute meds in case they happen to be taken close together.

Compared to other abortive medications such as the triptans and NSAIDS, these medications are not associated with medication overuse headache , which is great! They also have no addiction potential.

Compared to the triptans and ergots, these medications are NOT contraindicated in patients with stable cardiovascular or peripheral vascular disease or risk factors because they do not cause vasoconstriction of the arteries, which is a HUGE benefit.

Triptans are also contraindicated in patients with visual snow, persistent migraine aura, and migrainous stroke . However, gepants are felt to be safe for these patients, as well as those with hemiplegic migraine and migraine with brainstem aura . There are many patients who have been stuck without safe options since they have been unable to use standard therapies such as triptans due to other medical problems such as heart disease. So, we finally have a safe alternative for them, which is a highlight of these medications.

How Is The Cgrp Treatment Taken

Figure 1 from Calcitonin gene

There is more than one type of CGRP treatment available in the market today. Some of the main migraine medications that work by targeting CGRP include:

  • Fremanezumab
  • Epitinezumab
  • Atogepant

Most CGRP migraine treatments are administered by an injection with a needle or with an automatic pen. This process is similar to how some people with diabetes have to take insulin injections. It is expected that a CGRP medication that can be taken orally by mouth will become available soon.

The dosage of the CGRP drug will depend on your treatment plan, how often you get migraines in a month and the severity of your migraine attack and other associated symptoms. You may need to get the CGRP migraine treatment injection once or twice in a month. There are other CGRP migraine medications that you only need to take once every three months, and you can either administer the injections by yourself at home or go to your doctorâs clinic to have it injected there.

Recommended Reading: Why Does Caffeine Help Migraines

What Are The Possible Side Effects

The side effects of CGRP antibodies are generally mild or moderate. Redness or pain at the injection site is common. A small number of people had an allergic reaction to the drugs. Some people treated with Vyepti in clinical trials had an upper respiratory infection .1-4,9-12

Aimovig was linked to constipation and new or worsening high blood pressure. Doctors now monitor people taking Aimovig for rising blood pressure. You may need to take a different migraine drug if there is no other cause for your increasing blood pressure.1

Side effects can vary depending on the specific drug taken.

These are not all the possible side effects of CGRPs. Talk to your doctor about what to expect or if you notice any changes that concern you during treatment.

What Is The Difference Between Erenumab And Fremanezumab

The most important difference, from a biological standpoint is that fremanezumab targets the protein, erenumab targets the receptor. So, they have different targets. Practically speaking, they are both delivered as a single subcutaneous injection, or fremanezumab can be delivered as three injections once every three months. Their target is different, and that is something that I think is important, because it may be because their targets different one antibody may be effective, whereas another may not be. That would be great for patients who dont respond to one, if they can respond to another.

Recommended Reading: How To Get A Migraine

Cardiovascular And Pulmonary System

1. CGRP plays an important role in resisting the onset of hypertension how relevant is this when prescribing to young patients, particularly those at higher risk for HTN? How much does vascular dilation redundancy matter ?

2. With the onset of HTN, there is a compensatory release of CGRP: how relevant is this, and what effects do the antagonists have? In the face of HTN, CGRP release may become attenuated over time. There have been conflicting studies as to the amount of plasma CGRP present in those with HTN. To date, the antagonists have not appeared to affect blood pressure. Will CGRP antagonists be studied in those with HTN? Will these be evaluated in the face of poorly controlled HTN? Deletion of RAMP 1, for example, has been associated with cytokine production and HTN. Is this clinically relevant?

3. CGRP may delay or protect against the development of cardiovascular disease. For which patients is this relevant? CGRP is the most potent of all the vasodilators, so how might this influence prescribing for higher risk patients?

4. The effect of CGRP on the expression of endothelial nitric oxide synthase : depleting CGRP may lead to enhanced loss of eNOS what is the clinical relevance?

5. CGRP depletion may produce oxidative stress in the aorta how clinically relevant is this?

7. There is polymorphism with the CALC 1 gene is this clinically relevant in light of mAb use?

17. Is CGRP a vasodilator in both smaller and larger cerebral arteries?

Amylin Adrenomedullin And Cgrp Receptors

Spotlight on Migraine – Episode 16 – The New CGRP Blocking Migraine Treatments

1. The AMY 1 receptor , along with the ADM 1 and ADM 2 receptors, also have affinity for the CGRP ligand . Amylin, while mostly involved with glucose regulation, may be important in other functions .

2. CGRP also functions at the amylin receptors what is the result of blocking CGRP on the functioning of the amylin receptor. If one blocks the CGRP receptor, versus the ligand, is there a clinically relevant difference? By blocking the CGRP receptor, versus the ligand, CGRP may still attach to the amylin receptors.

3. Adrenomedullin competes with CGRP at the receptor site, and under certain conditions, ADM may actually compete with and displace CGRP from the receptor. If the CGRP antagonists affect the actions of ADM, what clinical effects might we see, over the long-term?

4. The ADM 1 and 2 receptors also have affinity for the CGRP ligand. What effects may occur from lowering CGRP, with regards to these other receptors?

5. Intermedin is a peptide with affinity for this family of receptors. What effect may occur from blocking some of the IMD effects?

6. What are the effects, after blocking CGRP, on these other ligands and receptors with regard to the vasodilator effects?

You May Like: Can Ocular Migraines Cause Numbness

Dysfunctional Nerve Signaling And Migraine

Migraine is a result of dysfunctional nerve signaling. Key players are the trigeminal nerves and CGRP, a signaling molecule. The trigeminal nerve runs from the brain to the face. It is responsible for sensation in the face and head, and some jaw movement.

CGRP is a small protein that transmits signals in the brain. Sensory nerves produce and release CGRP. Drugs that block CGRP help prevent and treat migraine. Other names for this class of drugs are: CGRP mAbs, CGRP inhibitors, or CGRP antagonists.

Do Preclinical Studies Give Reason To Be Concerned About Side Effects

CGRP is an ubiquitous peptide that is not only involved in migraine, but also in several physiological processes and in homeostatic responses during pathophysiological conditions . As such, it is vital to consider the possible side effects caused by the non-selective blockade of α- and β-CGRP with the CGRP -antibodies. As discussed in the previous section, the adverse events of the Phase II trials were mild , but it should be noted that the duration of these trials is not sufficient to see the long-term effects of continuingly blocking CGRP or its receptor.

Fig. 3

Possible side effects after long-term exposure to CGRP -antibodies. An overview of the organ systems where CGRP and the receptor are present and possible side effects that could be caused by the non-selective blockade of α- and β-CGRP with the CGRP -antibodies

In the cardiovascular system, CGRP is present in nerve fibers that innervate blood vessels and the heart , and participates in the regulation of blood pressure . Furthermore, it has also been described to have a role in the maintenance of vascular homeostasis during ischemic events and in tissue remodeling in pulmonary hypertension . This protective role raises a concern, since migraine patients present an increased cardiovascular risk . This topic was recently reviewed elsewhere . Hence, it is important to consider preexisting cardiovascular risk factors in patients to prevent a possible cardiovascular event.

Read Also: Can Ocular Migraines Cause Numbness

Skin Wound Healing Burns And Bone Health

1. CGRP contributes to flushing and thermoregulation what are the effects of blocking CGRP on these functions? In blushing syndromes , CGRP release is involved. Would blocking CGRP affect these syndromes? Is there an effect on Raynauds symptoms?

2. What clinical effect results from dampening the CGRP effects on local skin edema and itch? CGRP can inhibit allergic conditions, such as certain types of dermatitis . What effects on dermatitis might be seen by inhibiting CGRP? Loss of alpha CGRP-containing nerves may be associated with cold hypersensitivity. CGRP may have a role in temperature regulation. Could inhibiting CGRP be clinically relevant with these issues?

3. CGRP facilitates tissue repair and wound healing. These effects are mediated via vasodilation, upregulating VEGF expression, and by limiting inflammatory processes. CGRP also promotes revascularization. What effect does blocking CGRP have on wound healing? Which receptor does CGRP engage with to facilitate wound healing? Should at-risk patients for wound healing be prescribed these antagonists with caution?

4. CGRP plays some role in regeneration of the skin, via promoting proliferation of keratinocytes. Will skin be able to regenerate as well after CGRP is diminished?

5. For those with burns, CGRP and SP facilitate acute edema formation. What is the clinical relevance of knocking out CGRP for those with more severe burns?

Background: The Role Of Cgrp In Migraine

Figure 1 from CGRP and migraine: Could PACAP play a role ...

The trigeminal nerve runs from the brain to the face. It is responsible for sensation in the face and head. It is also responsible for jaw movement, such as biting and chewing. It has three branches that go to the eye and forehead , cheek , and jaw .

CGRP is a neuropeptide, a small protein that transmits signals in the brain. Sensory nerves produce and release CGRP.

CGRP has an important role in the current theory of migraine.2 At the start of a migraine attack, the trigeminal nerve releases CGRP. CGRP causes blood vessels in the head to swell. It contributes to some inflammation around the brain. Trigeminal pain pathways are activated.

There is a lot of evidence that CGRP has an important role in migraine.1 For example:

  • Blood levels of CGRP go up during a migraine attack.
  • People with migraine have higher CGRP levels between attacks than people without migraine normally have.
  • CGRP levels are higher in people with chronic migraine than episodic migraine.

Recommended Reading: What Piercing Is For Migraines

How Do Cgrp Antibodies Work

CGRP antibodies disrupt the CGRP process. The lock-and-key analogy is helpful for understanding how they do this. The CGRP protein is the key. The CGRP receptor is the lock. When the key opens the lock, the pain process begins or worsens. Drugs that block the lock or change the shape of the key interfere with the function of CGRP and are useful treatments for migraine.

One CGRP antibody blocks the lock:1

What Are The Benefits Of The Cgrp Migraine Treatment

The CGRP migraine treatments are believed to work best for people who have not got any relief from other conventional migraine treatments. A 2018 study discovered that nearly a third of people using this novel treatment-experienced 50 percent lesser migraines. The study also found that the migraine symptoms in the participants lasted for fewer days. Another study found that a third of the participants with migraines experienced 75% improvement in the frequency and severity of their migraine symptoms.

In any case, certain migraine medications may automatically stop being effective if they are used for a long time. As of now, CGRP migraine treatments have not been found to lose their effect after a certain period of time on treating and preventing migraines.

CGRP migraine treatments are generally only needed once or twice a month for most. This makes it easier for people who have migraines to not miss their medication dose. At the same time, people do not need to wait to experience a migraine attack in order to get treated.

Also Check: Va Benefits For Migraines

Can I Still Use My Cgrp Mab With The Covid

This hasnt been a reported issue thus far. There is no current evidence for an interaction between the Covid-19 vaccine and CGRP mAbs, the same as any other vaccine. This has also been stated by the American Migraine Foundation. Patients receiving CGRP mAbs were not excluded from the Covid-19 vaccine trials. There is no evidence at this time that these treatments cannot be used along with receiving Covid-19 vaccination, nor do they need to be delayed or timed any differently in relation to receiving Covid-19 vaccination.

Most physicians feel that there should theoretically be no interaction or contraindication to receiving either of these treatments in relation to Covid-19 vaccination because they are entirely different proteins with different mechanisms of action. The Covid-19 vaccine stimulates the immune system to form antibodies against the virus, should you encounter it. The CGRP mAbs do not have any significant influence on the immune system .

Rarely, the immune system of some patients can form neutralizing antibodies against the CGRP mAbs, and this can weaken the effectiveness of these treatments in their ability to decrease migraine frequency and severity. However, this rarity really has nothing to do with the mechanism and how the Covid-19 vaccine works. So, it is not felt that the Covid-19 vaccine will lessen the effectiveness of these treatments, nor will these treatments lessen the effectiveness of the Covid-19 vaccine.

FIRST, LETS DECIDE WHERE TO START:

If A 70 Milligram Dose Of Erenumab Didnt Work Would It Benefit Patients To Get A 140 Milligram Dose

CGRP antibodies for migraine prevention – Part 1

Its too early to tell yet, but there may be some patients who respond to a higher dose. So, I would say that if youre getting a partial response, or no response in the first month, or two, its absolutely worth it to bump up the dose to see if 140 milligram will work. While the two doses didnt separate in the pivotal trials, theres some evidence in subgroup analysis that the 140 milligram dose may be more effective. Before someone has considered a treatment failure, I would want to see if they failed on the 140 milligram dose as well.

You May Like: What Is A Migraine Headache

How To Pick Between The Gepants And Cgrp Mabs For Migraine Prevention

So now that we suddenly have a plethora of new preventive migraine treatments working on different targets in the CGRP migraine pathway between the CGRP mAbs and the gepants, how do you know which you should try, or which might work best for you?

Here is what to ask yourself to help narrow down which to consider trying first for preventing migraine . Do you prefer taking a pill, a once monthly self-injection , or a 30 minute quarterly IV infusion?

If you prefer a pill, the options are the gepants and include either Nurtec every other day or Qulipta once daily.

If you prefer a once monthly self-injection, the options are the CGRP mAbs and include Aimovig, Emgality, and Ajovy.

If you prefer a once quarterly 30-minute IV infusion, then the only option is the newest CGRP mAb called Vyepti.

Understanding Fremanezumab The Latest Fda

In a big win for the migraine community, fremanezumab , was recently approved by the FDA for the treatment and prevention of migraine. 2018 was a landmark year for this new class of treatments specifically designed for migraine. The FDA approved the first monoclonal antibody, erenumab in May 2018. Clinical trials for both treatments found them to be effective at reducing headache frequency with few side effects.

In a recent Facebook Live hosted by the American Migraine Foundation, Dr. David Dodick, Chair of the American Migraine Foundation and Professor of Neurology at the Mayo Clinic Arizona, discussed the latest CGRP developments with the migraine community and answered questions about the two FDA-approved treatments for migraine. Read on for his responses to audience questions:

Don’t Miss: What Is A Migraine Headache

RELATED ARTICLES

Popular Articles